UnknownNCT05751525

Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome

A short description of this study’s research objective has not yet been verified.

Observational studyAges 2–50Multiple countriesADHD

The study in practice

Understand this study

Who could participate?

Listed age limits: 2 years to 50 years.

Listed locations: Chicago, United States · Rome, Italy and 2 more locationsSee all locations and recruitment
Activities: Medication exposure observed; not assigned by the study
Compensation: Payment and expense reimbursement have not been verified.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: July 1, 2016

Recruitment status: Unknown
Enrollment listed in the registry: 21
Sponsor: Royal Devon and Exeter NHS Foundation Trust
Sponsor type: Non-profit organization
Study type: Observational
Intervention type: Medication / drug
Study phase: Not clearly listed
Locations: United States, United Kingdom, Italy, ...
Age range: From 2 Years to 50 Years
Official registry ID: NCT05751525
Official title: Impact of Timing of Initiation of Sulphonylurea Therapy on Neurodevelopmental Outcomes in Individuals With Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome Due to the V59M Mutation in the KCNJ11 Gene

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Study ID: NCT05751525. We help you review the study, but cannot decide medical eligibility.

Recruitment & locations

Status unknown

Chicago, United States · Rome, Italy · Bergen, Norway

1 more locations

Exeter, United Kingdom

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Royal Devon and Exeter NHS Foundation Trust.

Does this study involve medication?

Yes. The study involves medication, including Sulfonylurea.

Who can participate?

Listed age limits: 2 years to 50 years.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me